Related Experiment Videos
Recombinant human granulocyte-macrophage colony-stimulating factor therapy and endogenous plasma GM-CSF, IL-3, IL-4
N Cetingül1, N Kütükçüler, M Kantar
1Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey.
Insights
Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) significantly shortened neutropenia duration in pediatric cancer patients. This treatment also altered cytokine levels, suggesting a potential therapeutic mechanism in managing chemotherapy side effects.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Chemotherapy-induced neutropenia poses a significant risk for pediatric cancer patients.
- Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) is a potential therapeutic agent to mitigate neutropenia.
Purpose of the Study:
- To evaluate the efficacy of rHuGM-CSF in reducing the duration of neutropenia in pediatric patients with solid tumors.
- To investigate the impact of rHuGM-CSF therapy on endogenous cytokine levels (GM-CSF, IL-3, IL-4) and their correlation with hematological parameters.
Main Methods:
- A comparative study involving ten pediatric patients with solid tumors receiving rHuGM-CSF and eight control patients not receiving the treatment.
- Measurement of endogenous plasma GM-CSF, IL-3, and IL-4 levels in patients and healthy children.
- Correlation analysis between cytokine levels and absolute neutrophil counts, platelet counts, and rHuGM-CSF administration.
Main Results:
- rHuGM-CSF treatment significantly decreased the duration of the neutropenic phase.
- Plasma GM-CSF, IL-3, and IL-4 levels were significantly higher in neutropenic patients compared to healthy children.
- IL-3 levels correlated positively with platelet counts, and IL-4 levels correlated with GM-CSF levels. rHuGM-CSF therapy increased plasma GM-CSF and decreased IL-4 levels.
Conclusions:
- rHuGM-CSF is effective in shortening neutropenia duration in pediatric cancer patients.
- rHuGM-CSF therapy modulates endogenous cytokine profiles, with potential implications for managing chemotherapy-induced complications.
- Elevated IL-4 levels in osteosarcoma patients warrant further investigation.
Abstract:
Ten pediatric patients with solid tumors and chemotherapy-induced neutropenia were given recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM CSF). The duration of the neutropenic phase was then compared with the results obtained from eight patients also with solid tumors, but not treated with rHuGM-CSF. It was found that rHuGM-CSF treatment significantly decreased the duration of the neutropenic phase. Endogenous plasma GM-CSF, IL-3, and IL-4 levels were also measured in the study group and in healthy children. No significant correlation has been found between plasma GM-CSF concentrations and absolute neutrophil counts. However, IL-3 levels of the neutropenic patients positively correlated with platelet counts. Furthermore, IL-4 concentrations were positively correlated with the GM-CSF level in the same individual. Plasma GM-CSF, IL-3, and IL-4 levels in the neutropenic solid tumor group were found to be significantly higher than those in healthy children. Plasma IL-4 levels were significantly elevated in patients with osteosarcoma as compared to patients with other solid tumors. Although rHuGM-CSF has a half-life of only two to three hours, one day after rHuGM-CSF therapy, plasma GM-CSF levels were found to be higher than initial values. In contrast, plasma IL-4 values decreased significantly after administration of rHuGM-CSF. The probable mechanisms for the changes in cytokine levels are discussed.